SCHEMBL3584640

SCHEMBL3584640

O[CH]CCCCCCCCCCCCCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
SIGMAR1 Q99720 9/20 0.52
MAOA P21397 1/20 0.50
MAOB P27338 2/20 0.48
TRPV1 Q8NER1 1/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC2 Q92769 2/20 0.47
ALOX5 P09917 1/20 0.47
IGF1R P08069 1/20 0.47
ALOX15 P16050 1/20 0.47
HDAC3 O15379 1/20 0.47
MAPK1 P28482 1/20 0.47
ADRA1A P35348 1/20 0.47
HDAC4 P56524 1/20 0.47
SLC6A3 Q01959 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3587150 1.00 MAPT (0.53) MAPTRXFP1SIGMAR1MAOAMAOB
SCHEMBL3600859 1.00 MAPT (0.53) MAPTRXFP1SIGMAR1MAOAMAOB
SCHEMBL3601330 1.00 MAPT (0.53) MAPTRXFP1SIGMAR1MAOAMAOB
SCHEMBL3597537 1.00 MAPT (0.53) MAPTRXFP1SIGMAR1MAOAMAOB
SCHEMBL3586717 1.00 MAPT (0.53) MAPTRXFP1SIGMAR1MAOAMAOB
SCHEMBL3592734 1.00 MAPT (0.53) MAPTRXFP1SIGMAR1MAOAMAOB
SCHEMBL10516477 1.00 MAPT (0.53) MAPTRXFP1SIGMAR1MAOAMAOB
SCHEMBL4469893 1.00 MAPT (0.53) MAPTRXFP1SIGMAR1MAOAMAOB
SCHEMBL3602230 1.00 MAPT (0.53) MAPTRXFP1SIGMAR1MAOAMAOB
SCHEMBL3591598 0.91 HDAC3 (0.50) MAPTRXFP1SIGMAR1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741242-B2 Prepared by crosslinking a homogenized an addition polymer containing units from an unsaturated aryl-containing glycidyl ether or ester and an unsaturated alcohol or carboxylic acid and a zero-valent Pd compound to physically deposit the Pd compound on the polymer; oxidizing alcohols to aldehydes WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-06-22 US disclosed
EP-1537913-B1 PALLADIUM CATALYST COMPOSITION WAKO PURE CHEMICAL INDUSTIES L (JP) 2009-07-01 EP disclosed
US-20060019822-A1 Palladium catalyst composition JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2006-01-26 US disclosed
EP-1537913-A1 PALLADIUM CATALYST COMPOSITION Wako Pure Chemical Industies, Ltd. (JP) 2005-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019822-A1 Palladium catalyst composition ODC1, NUDC, ADH1C MAPT 3058/4885RXFP1 4885/4885SIGMAR1 3068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.